UCB SA (UCB.BR) Stock Fundamental Analysis

EBR:UCB • BE0003739530

252.3 EUR
+3.9 (+1.57%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

UCB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. UCB has an average financial health and profitability rating. UCB is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make UCB a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year UCB was profitable.
  • UCB had a positive operating cash flow in the past year.
  • Each year in the past 5 years UCB has been profitable.
  • UCB had a positive operating cash flow in each of the past 5 years.
UCB.BR Yearly Net Income VS EBIT VS OCF VS FCFUCB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

  • With a Return On Assets value of 7.75%, UCB perfoms like the industry average, outperforming 57.69% of the companies in the same industry.
  • UCB has a Return On Equity of 13.76%. This is comparable to the rest of the industry: UCB outperforms 57.69% of its industry peers.
  • UCB's Return On Invested Capital of 11.63% is in line compared to the rest of the industry. UCB outperforms 59.62% of its industry peers.
  • UCB had an Average Return On Invested Capital over the past 3 years of 4.35%. This is significantly below the industry average of 14.12%.
  • The last Return On Invested Capital (11.63%) for UCB is above the 3 year average (4.35%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROIC 11.63%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
UCB.BR Yearly ROA, ROE, ROICUCB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • With a decent Profit Margin value of 19.45%, UCB is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of UCB has remained more or less at the same level.
  • UCB has a Operating Margin of 26.58%. This is in the better half of the industry: UCB outperforms 67.31% of its industry peers.
  • UCB's Operating Margin has declined in the last couple of years.
  • UCB's Gross Margin of 73.38% is fine compared to the rest of the industry. UCB outperforms 65.38% of its industry peers.
  • In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
Industry RankSector Rank
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
UCB.BR Yearly Profit, Operating, Gross MarginsUCB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UCB is creating some value.
  • The number of shares outstanding for UCB remains at a similar level compared to 1 year ago.
  • UCB has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for UCB has been reduced compared to a year ago.
UCB.BR Yearly Shares OutstandingUCB.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
UCB.BR Yearly Total Debt VS Total AssetsUCB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 5.31 indicates that UCB is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.31, UCB is doing good in the industry, outperforming 78.85% of the companies in the same industry.
  • The Debt to FCF ratio of UCB is 2.43, which is a good value as it means it would take UCB, 2.43 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 2.43, UCB belongs to the best of the industry, outperforming 82.69% of the companies in the same industry.
  • A Debt/Equity ratio of 0.29 indicates that UCB is not too dependend on debt financing.
  • The Debt to Equity ratio of UCB (0.29) is better than 69.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Altman-Z 5.31
ROIC/WACC1.46
WACC7.96%
UCB.BR Yearly LT Debt VS Equity VS FCFUCB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 1.35 indicates that UCB should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.35, UCB is in line with its industry, outperforming 53.85% of the companies in the same industry.
  • UCB has a Quick Ratio of 1.01. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
  • UCB's Quick ratio of 1.01 is in line compared to the rest of the industry. UCB outperforms 53.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.01
UCB.BR Yearly Current Assets VS Current LiabilitesUCB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.41% over the past year.
  • The Earnings Per Share has been decreasing by -0.86% on average over the past years.
  • Looking at the last year, UCB shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
  • The Revenue has been growing slightly by 4.60% on average over the past years.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%

3.2 Future

  • UCB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.00% yearly.
  • Based on estimates for the next years, UCB will show a quite strong growth in Revenue. The Revenue will grow by 15.34% on average per year.
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue Next Year28.22%
Revenue Next 2Y20.45%
Revenue Next 3Y17.95%
Revenue Next 5Y15.34%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
UCB.BR Yearly Revenue VS EstimatesUCB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B
UCB.BR Yearly EPS VS EstimatesUCB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 39.30, the valuation of UCB can be described as expensive.
  • 61.54% of the companies in the same industry are cheaper than UCB, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.10, UCB is valued a bit more expensive.
  • With a Price/Forward Earnings ratio of 24.53, UCB is valued on the expensive side.
  • UCB's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. UCB is around the same levels.
Industry RankSector Rank
PE 39.3
Fwd PE 24.53
UCB.BR Price Earnings VS Forward Price EarningsUCB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 61.54% of the companies in the same industry are cheaper than UCB, based on the Enterprise Value to EBITDA ratio.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as UCB.
Industry RankSector Rank
P/FCF 41.41
EV/EBITDA 19.86
UCB.BR Per share dataUCB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of UCB may justify a higher PE ratio.
  • A more expensive valuation may be justified as UCB's earnings are expected to grow with 38.91% in the coming years.
PEG (NY)0.65
PEG (5Y)N/A
EPS Next 2Y43.7%
EPS Next 3Y38.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.39%, UCB is not a good candidate for dividend investing.
  • UCB's Dividend Yield is slightly below the industry average, which is at 1.89.
  • With a Dividend Yield of 0.39, UCB pays less dividend than the S&P500 average, which is at 1.80.
Industry RankSector Rank
Dividend Yield 0.39%

5.2 History

  • The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
UCB.BR Yearly Dividends per shareUCB.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • UCB pays out 19.82% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of UCB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP19.82%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
UCB.BR Yearly Income VS Free CF VS DividendUCB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
UCB.BR Dividend Payout.UCB.BR Dividend Payout, showing the Payout Ratio.UCB.BR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

UCB SA

EBR:UCB (2/27/2026, 7:00:00 PM)

252.3

+3.9 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)07-21
Inst Owners41.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap49.07B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts73.85
Price Target282.94 (12.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.39%
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.49%
PT rev (3m)6.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)3.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.27%
Revenue NY rev (3m)4.16%
Valuation
Industry RankSector Rank
PE 39.3
Fwd PE 24.53
P/S 7.17
P/FCF 41.41
P/OCF 31.14
P/B 5.07
P/tB 45.15
EV/EBITDA 19.86
EPS(TTM)6.42
EY2.54%
EPS(NY)10.28
Fwd EY4.08%
FCF(TTM)6.09
FCFY2.41%
OCF(TTM)8.1
OCFY3.21%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.65
PEG (5Y)N/A
Graham Number84.8
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROCE 13.73%
ROIC 11.63%
ROICexc 13.71%
ROICexgc 58.2%
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
FCFM 17.3%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Debt/EBITDA 1.15
Cap/Depr 61.48%
Cap/Sales 5.71%
Interest Coverage 16.4
Cash Conversion 64.17%
Profit Quality 88.96%
Current Ratio 1.35
Quick Ratio 1.01
Altman-Z 5.31
F-Score9
WACC7.96%
ROIC/WACC1.46
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year28.22%
Revenue Next 2Y20.45%
Revenue Next 3Y17.95%
Revenue Next 5Y15.34%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year162.81%
EBIT Next 3Y59.8%
EBIT Next 5Y41.09%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%

UCB SA / UCB.BR FAQ

What is the fundamental rating for UCB stock?

ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.


Can you provide the valuation status for UCB SA?

ChartMill assigns a valuation rating of 4 / 10 to UCB SA (UCB.BR). This can be considered as Fairly Valued.


Can you provide the profitability details for UCB SA?

UCB SA (UCB.BR) has a profitability rating of 6 / 10.


What are the PE and PB ratios of UCB SA (UCB.BR) stock?

The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 39.3 and the Price/Book (PB) ratio is 5.07.


What is the earnings growth outlook for UCB SA?

The Earnings per Share (EPS) of UCB SA (UCB.BR) is expected to grow by 60.25% in the next year.